Cogent Biosciences, Inc. COGT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $75.37M-0.3% | $75.56M+9.5% | $68.99M+10.9% | $62.2M-1.3% | $63.03M+1.6% | ||
| $28.24M+18.0% | $23.93M+66.6% | $14.37M+7.4% | $13.38M+12.4% | $11.9M+1.8% | ||
| $103.61M+4.1% | $99.49M+19.4% | $83.36M+10.3% | $75.58M+0.9% | $74.93M+1.6% | ||
| -$103.61M-4.1% | -$99.49M-19.4% | -$83.36M-10.3% | -$75.58M-0.9% | -$74.93M-1.6% | ||
| $1.21M-5.9% | $1.29M-11.7% | $1.46M+365% | $314K— | $0— | ||
| $7.61M+38.9% | $5.48M+40.9% | $3.89M+63.8% | $2.37M-19.6% | $2.95M-23.5% | ||
| $6.26M— | —— | $2.43M+18.1% | $2.05M-30.3% | $2.95M-49.3% | ||
| —— | -$1.8M0.0% | -$1.8M0.0% | -$1.8M0.0% | -$1.8M— | ||
| -$97.35M+5.0% | -$102.49M-26.6% | -$80.93M-10.1% | -$73.53M-2.1% | -$71.99M-6.0% | ||
| -$0.53+13.1% | -$0.61-22.0% | -$0.50+5.7% | -$0.53-1.9% | -$0.52-4.0% | ||
| -$0.53+13.1% | -$0.61-22.0% | -$0.50+5.7% | -$0.53-1.9% | -$0.52-4.0% | ||
| 162.2M+25.8% | 128.9M-6.3% | 137.6M+20.2% | 114.5M+1.0% | 113.3M+9.1% | ||
| 162.2M+25.8% | 128.9M-6.3% | 137.6M+20.2% | 114.5M+1.0% | 113.3M+9.1% | ||
| -$98.12M+4.1% | -$102.35M-26.8% | -$80.74M-9.6% | -$73.68M-2.0% | -$72.27M-5.7% | ||
| -$135K— | —— | —— | —— | -$0— | ||
| -$770K— | —— | $195K+229% | -$151K+46.6% | -$283K— | ||
| -$770K— | —— | $195K+229% | -$151K+46.6% | -$283K— | ||
| -$140K-2,233% | -$6K-100% | -$3K+50.0% | -$6K-20.0% | -$5K-100% | ||
| -$103.61M-4.1% | -$99.49M-19.4% | -$83.36M-10.3% | -$75.58M-0.9% | -$74.93M-1.6% | ||
| -$102.98M-4.2% | -$98.85M-19.5% | -$82.71M-10.4% | -$74.93M-0.9% | -$74.29M-1.6% | ||
| -$102.98M-4.2% | -$98.85M-19.5% | -$82.71M-10.4% | -$74.93M-0.9% | -$74.29M-1.6% | ||
| -$103.61M-4.1% | -$99.49M-19.4% | -$83.36M-10.3% | -$75.58M-0.9% | -$74.93M-1.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cogent Biosciences, Inc.'s revenue?
- Cogent Biosciences, Inc. (COGT) generated $7.9M in revenue over the trailing twelve months, down 65.0% year over year.
- Is Cogent Biosciences, Inc. profitable?
- Cogent Biosciences, Inc. is not currently profitable: it reported a net loss of $354.3M over the trailing twelve months, a -950.4% net margin.
- What is Cogent Biosciences, Inc.'s earnings per share?
- Cogent Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.17.
- Where does Cogent Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
